; Earp et al., 1995) 
Introduction
macrophages (Higashiyama et al., 1991) . As are other members of the EGF family, HB-EGF is synthesized as a The biological activities of the epidermal growth factor transmembrane precursor that can be cleaved enzym-(EGF) family of ligands, which has at least seven members, atically to release a soluble 14-20 kDa form (Higashiyama is mediated by their interaction with receptor tyrosine et al., 1992; Raab et al., 1994) . The soluble form of HBkinases (RTKs), transmembrane proteins that convert EGF is a potent paracrine and/or autocrine mitogen for extracellular growth factor signals into intracellular fibroblasts, smooth muscle cells (SMC) and keratinocytes enzymatic activities. At least four EGF receptors have (Higashiyama et al., 1991; Marikovsky et al., 1993) . It been identified that bind the EGF-like ligands. These has also been shown to be a potent chemoattractant for receptors have been designated as HER1, HER2, HER3 SMC (Higashiyama et al., 1993) . HB-EGF has been and HER4 as a result of homologies to the originally implicated in vivo as having a role in wound healing described human EGF receptor; or erbB-1, erbB-2, erbB-3 and erbB-4 as a result of homologies to the v-erbB (Marikovsky et al., 1993) and in processes involving SMC hyperplasia such as atherosclerosis (Miyagawa et al., 1995) , pulmonary hypertension (Powell et al., 1993) and uterine leiomyomas (Mangrulkar et al., 1995) . Given the possible physiological and pathological roles of HB-EGF, we have been interested in analyzing its receptor interactions. Like most of the HER ligands, HB-EGF binds to and activates HER1. It competes for the binding of [ 125 I]EGF to A431 cells which express a very abundant amount of HER1 (Higashiyama et al., 1991) ; it stimulates tyrosine phosphorylation of HER1 (Higashiyama et al., 1992) ; and it induces proliferation of cells transfected to overexpress HER1, both as a paracrine and as a juxtacrine factor (Aviezer and Yayon, 1994; Blotnick et al., 1994; Higashiyama et al., 1995) . However, it is possible that HB-EGF might interact with other EGF receptor subtypes. For example, our preliminary experiments have indicated that [ 125 I]HB- not HER1 (Plowman et al., 1993a) . Accordingly, in order HER3 (lane 3) and HER4 (lane 4) were immunoprecipitated with antito determine whether HB-EGF could interact directly with HER1, anti-HER2, anti-HER3 and anti-HER4 antibodies, respectively, separated on a 6% SDS-PAGE gel and the radioactive complexes EGF receptors other than HER1, we obtained NIH 3T3 solely (Zhang et al., 1996) . Here, we demonstrate that antibody (lane 1), in the presence of 5 μg/ml of neutralizing HB-EGF binds to HER4, induces tyrosine phophorylation HB-EGF is a potent chemotactic factor but not a mitogen for cells expressing HER4, in contrast to the ability of HB-EGF to stimulate both these activities in cells expressing et al., 1994) , but cross-linking to HER4 has not. Accordingly, to confirm that HB-EGF interacts with HER4, HER1. These results suggest that HB-EGF is a ligand for HER4 as well as HER1 but that these two receptors neutralizing monoclonal antibodies directed against the extracellular domain of human HER4 were analyzed for mediate different biological activities in response to this single ligand. compared with a phosphate-buffered saline (PBS) control ( Figure 1B , lane 1). On the other hand, a similar concentraConfluent NIH 3T3 cell stable transfectants expressing either human HER1, HER2, HER3 or HER4 alone (Zhang tion of anti-HER1 neutralizing antibody had no effect ( Figure 1B , lane 2). From the combination of crosset al., 1996) were incubated with 10 ng/ml of [ 125 I]HB-EGF, chemically cross-linked and lysed (Figure 1 ). The linking, immunoprecipitation and immunoneutralizing experiments, it was concluded that HB-EGF binds to lysates of cell lines expressing each of the four receptors were immunoprecipitated with the corresponding specific HER4 as well as to HER1 and that HB-EGF-HER4 binding is not dependent on heterodimerization of HER4 polyclonal anti-HER antibodies. After separation on 6% SDS-PAGE gels, single cross-linked complexes were with HER1. found associated only with the lysates of NIH 3T3 cells expressing HER1 or HER4 ( Figure 1A , lanes 1 and Binding of EGF family ligands to cells expressing either HER1 or HER4 4, respectively). The [ 125 I]HB-EGF-HER4 complex, of 190-200 kDa, was slightly larger than the [ 125 I]HB-EGF has been shown to interact with HER1 but not HER4 (Plowman et al., 1993a) while HRG interacts with HER4 EGF-HER1 complex, of~180-190 kDa, consistent with the cross-linking of 14 kDa [ 125 I]HB-EGF to 180 kDa but not HER1 (Plowman et al., 1993b Figure 1A , cross-linked complexes with cells expressing either HER1 or HER4 (Figure 2 , lanes 1 and 4, respectively). In this lanes 2 and 3, respectively).
The cross-linking of [ 125 I]HB-EGF to A431 cell HER1 experiment, the relative cross-linking intensity of HB-EGF was greater for HER1 than HER4, unlike the experireceptors has been described previously (Higashiyama Figure 1A , except that no immuno-(A) Increasing amounts of 125 I-labeled ligand were added to NIH 3T3 precipitation step was included. cells expressing either HER1 or HER4. Non-specific binding was determined by competition with a 200-fold excess of unlabeled ligand and subtracted from total binding. After binding, the cells were ment shown in Figure 1 . This discrepancy might be washed, lysed, and the cell-associated radioactivity was determined explained by the fact that in Figure 2 , no immunoprecipiusing a γ-counter. Each point represents the mean of two independent tation was carried out after cross-linking, thus minimizing Figure 3A ) and Scatchard plots ( Figure 3B ) were generated. Dissociation constants (K d ) and numbers of expressing HER1 or HER4 were incubated with or without 100 ng/ml of HB-EGF and, for comparison, with 100 ng/ binding sites were determined using the LIGAND linear regression program (Table I) . Several conclusions were ml EGF or HRG-β1. After immunoprecipitation with anti-HER1 or anti-HER4 antibody, tyrosine phosphorylation drawn from the Scatchard analysis as follows. (i) The Scatchard plots were in all cases curvilinear and suggested of the receptors was analyzed by Western blotting using anti-phosphotyrosine antibodies ( Figure 4A ) and quantitthe existence for each ligand-receptor pair of two classes of binding sites, high and low. High and low affinity ated ( Figure 4B ). HB-EGF ( Figure Figure 3 . Mean K d s, mean binding sites/cell and their standard deviations were calculated.
Fig. 4. Tyrosine phosphorylation of EGF receptors in cells expressing HER1 or HER4. (A) NIH 3T3 cells expressing HER1 (lanes 1-4) or HER4
(lanes 5-8) were starved for 24 h in a serum-free medium and incubated for 10 min on ice and then for 5 min at 37°C without ligand (lanes 1 and 5) or with 100 ng/ml of HB-EGF (lanes 2 and 6), EGF (lanes 3 and 7) or HRG-β1 (lanes 4 and 8). Cells were lysed and samples of lysates were immunoprecipitated with polyclonal anti-HER1 (lanes 1-4) or anti-HER4 (lanes 4-8) antibodies, followed by SDS-PAGE (6%) and Western blotting with anti-phosphotyrosine antibody. (B) The receptor-associated tyrosine phosphorylation stimulated by HB-EGF and EGF in cells expressing HER1 or HER4 shown in (A) was quantitated by densitometry.
MB-453 breast adenocarcinoma cells are known to express HER2, HER3 and HER4, but not HER1 (Plowman et al., 1993a) . Thus, these cells are useful for analyzing HER1-independent stimulation of EGF receptors by HB-EGF. Accordingly, MDA-MB-453 cells were incubated with HB-EGF or EGF, followed by immunoprecipitation of cell lysates with the various anti-HER antibodies and Western blotting using anti-phosphotyrosine antibodies. ating (our unpublished data). Primary rat astrocytes were The ability of HB-EGF to stimulate HER4 tyrosine incubated with either HB-EGF or EGF, and their lysates phosphorylation was also tested in non-engineered cells that express endogenous EGF receptors ( Figure 5 ). MDAwere immunoprecipitated and analyzed for tyrosine Primary rat astrocytes were incubated with HB-EGF or EGF, lysed, and lysates were immunoprecipitated with anti-HER1 (lanes 1, 3 and 5) or anti-HER4 (lanes 2, 4 and 6) antibodies and analyzed for tyrosine phosphorylation as described in Figure 4A . No stimulation (lanes 1 and 2); 100 ng/ml HB-EGF (lanes 3 and 4); 100 ng/ml EGF (lanes 5 and 6).
phosphorylation of HER1 and HER4 by Western blotting can occur even when HER1 is activated in the same cell. Whether the tyrosine phosphorylation of HER4 in astrocytes is due to a direct activation or is a result of [ 3 H]thymidine incorporation into DNA was measured (not shown). It was concluded that HER1 and HER4, while heterodimerization with HER1 is not known at present.
binding HB-EGF, differ in their ability to respond to HB-EGF as a mitogen.
HB-EGF stimulates proliferation of cells expressing HER1 but not of cells expressing HER4
HB-EGF binds to HER1 and stimulates the proliferation HB-EGF stimulates chemotaxis of cells expressing HER1 and of cells expressing HER4 of cells expressing this receptor (Aviezer and Yayon, 1994; Blotnick et al., 1994) . Since HB-EGF binds to HER4 and HB-EGF was shown previously to be a potent chemoattractant for aortic SMC (Higashiyama et al., 1993) . stimulates tyrosine phosphorylation of this receptor, it would seem reasonable that HB-EGF might stimulate the Accordingly, the ability of HB-EGF, and by comparison EGF or HRG-β1, to induce a chemotactic response in proliferation of cells expressing HER4 as well. Accordingly, cells expressing HER1 or HER4 were treated with cells expressing HER1 or HER4 was analyzed using a modified Boyden chamber assay (Figure 8 ). Both HB-HB-EGF and, for comparison, with EGF, HRG-β1 or fibroblast growth factor 2 (FGF-2). Cell number was EGF and EGF stimulated chemotaxis of cells expressing HER1 in a dose-dependent manner ( Figure 8A , left). measured after a 72 h incubation in serum-free medium (Figure 7 ). HB-EGF increased the number of cells EGF was more potent, with half-maximal stimulation at Ͻ0.1 ng/ml, while HB-EGF required~5 ng/ml to obtain expressing HER1 by 3-fold in a dose-dependent manner ( Figure 7A ). However, it did not stimulate the proliferation the same effect. On the other hand, when cells expressing HER4 were tested, HB-EGF was found to be a potent of cells expressing HER4 despite its ability to activate this receptor. As expected, EGF was mitogenic for cells chemotactic factor with half-maximal stimulation at 1 ng/ml, while EGF stimulated very little if any chemotaxis expressing HER1 but not mitogenic for cells expressing HER4 ( Figure 7B ), consistent with its lack of HER4 ( Figure 8A , right). The chemotactic effects of HB-EGF for cells expressing HER4 were inhibited by neutralizing binding. HRG-β1, which is a ligand for HER4, but not for HER1, stimulated the proliferation of HER4 cells anti-HER4 but not by neutralizing anti-HER1 antibodies (not shown), suggesting that the chemotactic effects were slightly but did not stimulate the proliferation of HER1 cells ( Figure 7C ). As a control to show that the cells not due to low levels of HER1. A checkerboard analysis demonexpressing HER4 are mitogenically responsive, FGF-2, which uses a different receptor system, stimulated a dosestrating that the migratory effects of HB-EGF on cells expressing HER1 and HER4 are indeed chemotaxis, which dependent proliferation of cells expressing HER4 or HER1 to the same degree ( Figure 7D) . Furthermore, the two cell is directed migration, rather than chemokinesis, which is increased random migration, is shown in Table II . Various types were equally responsive to 10% fetal bovine serum (FBS) with an 8-to 10-fold increase in cell number after concentrations of growth factor were administered to both upper and lower wells of the Boyden chamber apparatus. a 72 h incubation (not shown). Comparable results were obtained when the ability of the growth factors to stimulate When no growth factor was added to the upper wells, cells expressing HER1 and HER4 migrated towards HB-( Figure 8B, right) . In replicate experiments, the halfmaximal chemotactic stimulation by HB-EGF for cells EGF in the lower wells in a dose-dependent manner, as expressing HER4 (0.5-1.0 ng/ml) appeared to occur at in Figure 8 . However, when equal concentrations of HBreproducibly lower concentrations than for cells expressing EGF were added to both upper and lower wells to destroy HER1 (2.5-5.0 ng/ml). the gradient, very little or no HB-EGF-enhanced migration was observed with either cell type (Table II, bold diagonal HB-EGF stimulates association of PI3-K activity rows). Thus, HB-EGF does not stimulate migration in the with HER4 absence of a gradient, characteristic of chemotaxis. Using
The signal transduction pathways leading from RTKs to the same checkerboard assay, the effect of EGF on cell motility have been suggested to involve different stimulating the migration of HER1-transfected cells was forms of phosphoinositides (Cantley et al., 1991) . Studies also found to be predominantly chemotaxis (not shown).
with platelet-derived growth factor receptor-β (PDGFRThe ability of HB-EGF to stimulate chemotaxis was β) have demonstrated that PI3-K, an enzyme that phosalso compared with that of HRG-β1, a ligand for HER4 phorylates phosphoinositides at the 3Ј position of the but not HER1. HB-EGF, but not HRG-β1, stimulated inositol ring, is needed for the chemotactic response chemotaxis of cells expressing HER1 ( Figure 8B, left) , stimulated by PDGF-BB (Kundra et al., 1994 ; Wennström while HB-EGF and HRG-β1 were equally effective as et al., 1994b). As the cytoplasmic tail of HER4 but not chemotactic factors for cells expressing HER4, with half-HER1 (Fedi et al., 1994; Soltoff et al., 1994) was described maximal stimulation occurring at 0.5-1.0 ng/ml recently to contain a binding site for the p85 subunit of PI3-K (Cohen et al., 1996) , it was of interest to determine whether HB-EGF could induce the association of PI3-K activity with phosphorylated HER4. Accordingly, cells expressing HER4 were stimulated with HB-EGF or EGF and lysed, and the lysates were immunoprecipitated with a polyclonal anti-HER4 antibody. PI3-K activity co-precipitating with HER4 subsequently was measured using an in vitro kinase assay in which phosphorylation of PI in the presence of [γ-32 P]ATP to form [ 32 P]PI was analyzed by thin-layer chromatography (TLC) and autoradiography ( Figure 9A ). [ 32 P]PI immunoprecipitated from lysates of unstimulated cells expressing HER4 with anti-p85 antibodies was used as a standard and reflects the basal PI3-K activity of unstimulated cells ( Figure 9A , lane 4). The [ 32 P]PI on the TLC membrane was quantitated using a PhosphorImager ( Figure 9B ). HB-EGF stimulated a 2.6-fold increase ( Figure 9A , lane 2) in PI3-K activity associated with HER4 compared with non-stimulated cells ( Figure 9A , lane 1). EGF ( Figure 9A , lane 3), however, with previous results (Fedi et al., 1994; Soltoff et al., out at the same time using the same growth factor aliquots. The same 1994).
is true for the experiments shown in (B). The numbers of cells migrating through the membrane were counted under a microscope.
Wortmannin inhibits HB-EGF-stimulated
Each point represents the mean cell number and standard deviations of chemotaxis of HER4-expressing cells four independent wells. The chemotactic response stimulated with 10%
Wortmannin binds to the p110 subunit of PI3-K and FBS showed a 6.5 Ϯ 1.9-fold increase in cells expressing HER1 and a 4.7 Ϯ 0.8-fold increase in cells expressing HER4.
inhibits PI3-K activity (Yano et al., 1993) . Since HB-EGF Concentrations of ligand (ng/ml) added to the upper wells (horizontal lines) or lower wells (vertical lines) of the Boyden chamber apparatus are shown in italics. The number of cells which migrated to the lower wells is shown as a mean of measurements made in four independent wells. Standard deviations were ഛ10%. The numbers of cells which migrated in the absence of a concentration gradient (same concentration of ligand in the upper and lower wells) are shown in bold. Aviezer and Yayon, 1994). However, the result that HER4 is a receptor for HB-EGF is apparently a novel finding. NIH 3T3 cells expressing either HER1, HER2, HER3 or HER4 (Zhang et al., 1996) (Table I; Wada et al., 1990) and to that of HRG-β1 for HER4 which were plated into the upper wells of a Boyden chamber.
HER4 (Table I; Holmes et al., 1992) . HB-EGF also has 5 ng/ml of HB-EGF was added to the lower wells. Chemotaxis was measured as in Figure 8 . The baseline number of cells migrating in the low affinity binding sites for HER4 with a K d of~17 nM.
absence of HB-EGF was 150.
(iii) HB-EGF stimulates HER4 tyrosine phosphorylation and HER4 association of PI3-K activity in cells expressing solely HER4. (iv) HB-EGF is highly chemotactic, with induces HER4-associated PI3-K activity and stimulates a half-maximal stimulation at 0.5-1.0 ng/ml, for cells chemotaxis of cells expressing HER4, wortmannin was expressing solely HER4. Chemotaxis is inhibited by tested for its effects on HB-EGF-induced chemotaxis neutralizing anti-HER4, but not by neutralizing anti-HER1 of these cells (Figure 10 ). Wortmannin inhibited the antibodies. chemotactic response of cells expressing HER4 to HBSince HB-EGF also activates HER1, a receptor that can EGF in a dose-dependent and non-toxic manner. Complete activate the other EGF receptors indirectly by heteroinhibition of HB-EGF-induced chemotaxis occurred at dimerization (Wada et al., 1990; Soltoff et al., 1994 ; Riese 25-100 nM. At very high concentrations, ജ500 nM, et al., 1996b) , it was important to demonstrate that cells wortmannin also inhibited background chemotaxis in the expressing HER4 did not express any HER1 in order to absence of added growth factor. These results suggest that rule out the possibility that the effects of HB-EGF on PI3-K activity is involved in the signal transduction cells expressing HER4 were actually results of HER1-pathway of chemotaxis mediated by HER4.
HER4 heterodimerization. First of all, analysis of HER4 transfectants showed that these cells did not express detectable levels of HER1 when analyzed by Western
Discussion
blotting with anti-HER1 antibodies (Zhang et al., 1996) . HB-EGF is capable of binding to, and activating two Secondly, EGF, a well characterized ligand for HER1, did tyrosine kinase receptors, HER1 and HER4, but the not bind to or induce any cellular responses such as biological responses that result from these interactions tyrosine phosphorylation, chemotaxis or proliferation in differ. Activation of HER1 by HB-EGF results in chemocells expressing HER4, although, as expected, it stimulated taxis and in proliferation, while activation of HER4 results all of these activities in cells expressing HER1. Moreover, in chemotaxis but not in proliferation. Thus, this ligand EGF did not induce HER4 phosphorylation even in rat is capable of activating differential responses by binding primary astrocytes which express abundant HER1 and are to different receptors.
capable putatively of HER1-HER4 dimerization. Finally, The binding and activation of HER1 by HB-EGF neutralizing monoclonal antibodies directed against HER1 inhibited HB-EGF binding to, and activation of HER1 as confirms previous reports (Higashiyama et al., 1991 (Higashiyama et al., , 1992  expected, but did not abrogate any of the activities of HBThr654 by protein kinase C (PKC) results in a reduced proliferative response without affecting the migratory EGF for HER4.
The results presented here, as well as in previous studies response (Bowen et al., 1991; Chen et al., 1996) . Besides HB-EGF, we have found that the other known (Beerli and Hynes, 1996; Riese et al., 1996a,b) , suggest that EGF family ligands fall into at least three categories ligands for HER4, HRG-β1 ( Figure 8B ) and βC (our unpublished data), stimulate the migration of cells with respect to growth factor-receptor interactions. The first category includes EGF, TGF-α and AR which bind expressing HER4. On the other hand, EGF ( Figure 8A ), TGF-α and AR do not stimulate the migration of these to and activate HER1 directly. These growth factors do not induce receptor autophosphorylation or other cellular cells (our unpublished data) as expected, given that they do not bind to HER4. Unlike HB-EGF, HRG-β1 stimulates activities directly in cells expressing HER2, HER3 or HER4 unless HER1 is expressed as well, allowing the proliferation in cells expressing HER4. One possible explanation for this differential effect is that HRG-β1 formation of heterodimers. The second category includes the products of the HRG gene which, as we have coninteracts with HER4 to a greater extent than does HB-EGF. Compared with HB-EGF, HRG-β1 has a 2-fold firmed, do not interact directly with HER1 (Peles et al., 1992; Riese et al., 1995) . Instead, HRG is a ligand for higher affinity, has twice the number of high affinity binding sites and shows a 2-fold enhanced level of HER4 HER3 and HER4 (Plowman et al., 1993b) . HB-EGF falls into the third category, a ligand tyrosine phosphorylation. Thus HRG-β1 activation of HER4 may result in signal transduction that is quantitatthat can bind to and activate both HER1 and HER4 independently of each other without the necessity for ively or qualitatively different from that induced by HB-EGF resulting in proliferation. The ability of members of heterodimerization. βC appears to be in the same category as HB-EGF since βC activates tyrosine phosphorylation a receptor family, such as HER1 and HER4, to transduce different biological responses indicates that multiple of both HER1 and HER4 in the T47D breast tumor cell line which expresses all four known EGF receptor homologous EGF receptor subtypes have evolved to provide additional specificity in response to ligand subtypes, and the activation of HER4 in these cells is only partially attributable to heterodimerization (Beerli binding.
Our results suggest that activation and recruitment of and . Furthermore, βC induces tyrosine phosphorylation of both HER1 and HER4, but not of HER2 PI3-K might be involved in HER4-mediated chemotaxis. First of all, HB-EGF (Figure 9 ), HRG-β1 (our unpublished or HER3, in interleukin-3 (IL-3)-dependent lymphoid cell lines transfected individually with the various EGF data) and HRG-β2 (Cohen et al., 1996) stimulate association of PI3-K with HER4. Secondly, wortmannin, an receptors (Riese et al., 1996a) . Interestingly, HB-EGF does not activate HER4 in lymphoid cells expressing this inhibitor of PI3-K activity (Yano et al., 1993) , inhibits HB-EGF-stimulated migration of cells expressing HER4 receptor alone for reasons that are not clear (Riese et al., 1996b) . One possibility is that the lymphoid cells lack in a dose-dependent manner. However, a definitive role for PI3-K in HB-EGF-stimulated chemotaxis would require cell surface heparan sulfate proteoglycans which are known to enhance markedly HB-EGF binding and chemoinactivation of this receptor by site-directed mutagenesis of the HER4 PI3-K binding domain (Tyr1056; Cohen tactic activity (Higashiyama et al., 1993) . et al., 1996) or a dominant-negative strategy that would inactivate PI3-K (Wennström et al., 1994a) . Interestingly, activating HER1 or HER4. In particular, while HB-EGF is chemotactic for cells expressing either receptor, it is HB-EGF does not stimulate direct association of PI3-K with HER1, yet wortmannin inhibits chemotaxis of cells mitogenic for cells expressing HER1 but not for cells expressing HER4. Lack of HB-EGF mitogenic activity in expressing HER1 (our unpublished data). A plausible explanation is that HER1 associates with PI3-K indirectly cells expressing HER4 is not due to a lack of any growth potential in these cells since they are capable of a in these cells, for example via Grb2-associated binder-1 (Gab1) that can link Grb2 to PI3-K (Holgado-Madruga mitogenic response, for example in response to FGF-2. The mechanisms by which HB-EGF is able to stimulate et al., 1996) . HB-EGF might also stimulate indirect PI3-K interaction with HER4, resulting in an increased level proliferation of cells expressing HER1 but not HER4 are not understood as of yet. We have found that HBof total cellular PI3-K above and beyond the increase in direct HER4-associated PI3-K, but this possibility has not EGF stimulates relatively less tyrosine phosphorylation of HER4,~2-to 3-fold, as compared with HER1. In addition,
HB-EGF induces differential cellular responses when
been tested yet. In any case, the differential ability of HER4 and HER1 to bind PI3-K in response to HB-EGF while the K d s for both the high and the low affinity components of HB-EGF binding to HER1 as compared demonstrates clearly that there are differences in the signaling cascades generated by activating HER4 as comwith HER4 are similar, there are about twice the number of available binding sites for HB-EGF on the surface of pared with HER1. These differences could affect the local concentrations of PI3-K and/or its activity as well as the cells expressing HER1 compared with HER4. Thus, we speculate that HB-EGF, due to lowered binding and availability of binding sites for other signal transduction molecules. Differential recruitment of PI3-K activity in tyrosine phosphorylating ability, may not be able to mobilize the necessary signal transduction pathway molecresponse to HER4 or HER1 stimulation is supported further by our finding that wortmannin inhibits HER4-ules needed to stimulate proliferation via HER4. An alternative explanation for the lack of HB-EGF-induced mediated chemotaxis at significantly lower concentrations compared with HER1-mediated chemotaxis (our unpubproliferation of cells expressing HER4 is that signal transduction pathways that down-regulate proliferation are lished data).
A role for PI3-K in HER4-mediated chemotaxis, but activated when HER4 is stimulated by HB-EGF. For example, phosphorylation of EGF-activated HER1 at not necessarily mitogenesis, is consistent with previous and HER4 transcripts are strongly expressed in heart, once with PBS and 5-20 ng/ml of radioiodinated growth factor was skeletal muscle, brain and kidney  added in 1.5 ml of binding buffer (DMEM, 20 mM HEPES, pH 7.4, 0.1 Plowman et al., 1993a) . Targeted disruption of the HER4 mg/ml gelatin). After a 2 h incubation in a horizontal shaker, cells were gene generates clearly defined defects in the developing washed once with 2 M NaCl, 10 mM Tris-HCl, pH 7.4, and twice with ice-cold PBS. Increasing concentrations of radioiodinated ligands were added to the wells in 100 μl of PBS containing 1 mg/ml bovine serum albumin. After a 90 min incubation on ice, the cell layers were washed
Materials and methods
three times with ice-cold 2 M NaCl, 10 mM Tris-HCl, pH 7.4, to remove any ligand bound with low affinity to cell surface heparan sulfate Growth factors and antibodies (Moscatelli, 1987) . The cells were lysed with 0.2 M NaOH and bound Recombinant human HB-EGF and FGF-2 were provided by Dr J.Abraradioactivity was measured with a γ-counter. Non-specific binding was ham (Scios Nova, Mountainview, CA). Recombinant human HRG-β1 defined as the amount of binding obtained after adding a 200-fold excess (residues 177-241) was provided by Dr M.Sliwkowski (Genetech, Inc., of unlabeled ligand to cells together with the labeled ligand. The nonSouth San Francisco, CA). [ 125 I]ARIA-1 (the extracellular domain of specific binding, typically 10%, was subtracted from the total binding. recombinant chicken proARIA-1; 1.4ϫ10 4 c.p.m./ng) (Falls et al., 1993) Ligand binding data were used to generate saturation curves and was provided by Drs A. Goodearl and G.Fischbach (Harvard Medical Scatchard blots, and apparent K d values were determined by linear School, Boston, MA). Mouse monoclonal anti-phosphotyrosine antibody regression analysis using the LIGAND computer program (Munson and (4G10) was provided by Dr B.Drucker (Dana Farber Cancer Institute, Rodbard, 1980) . Boston, MA), and mouse monoclonal antibody directed against the p85 subunit of PI3-K by Dr L.Cantley (Harvard Medical School, Boston, Immunoprecipitation MA). Recombinant human EGF was purchased from Intergen. Sheep
Immunoprecipitation of growth factor-receptor complexes was carried polyclonal (#06-129) and mouse monoclonal (clone LA1) antibodies out following growth factor stimulation or [ 125 I]growth factor crossdirected against human HER1 were purchased from UBI. Mouse monolinking to cells. For immunoprecipitation following growth factor stimulaclonal antibody (clone H4.72.8) that detects the extracellular domain of tion, cells were grown to confluency in 176.6 cm 2 dishes and starved human HER4 was purchased from Neomarkers. Rabbit polyclonal for 24 h in a serum-free DMEM, 1% GPS. Cells were treated with HBantibodies raised against peptides corresponding to sequences from the EGF, EGF or HRG-β1 (100 ng/ml) suspended in DMEM, 1% GPS for cytoplasmic domains of human HER2 (C-18), HER3 (C-17) and HER4 10 min on ice followed by 5 min at 37°C. The cells were scraped into (C-18) were purchased from Santa Cruz Biotechnology Inc. Peroxidasea lysis buffer containing 1% NP-40, 10 mM Tris-HCl, pH 7.0, 1 mM conjugated rabbit anti-mouse IgG antibody was purchased from Sigma.
EDTA, 2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml aprotinin, Polyclonal rabbit anti-cow glial fibrillary acidic protein (GFAP) was 10 μg/ml leupeptin, 1 mM sodium orthovanadate, 10 mM sodium fluoride and 10 mM sodium pyrophosphate. Lysates were immunoprecipipurchased from DAKO.
